research use only

Dexrazoxane

Cat.No.S5651

Dexrazoxane (ICRF-187) is an anticancer drug able to block mitosis and to arrest dividing cells. It is an iron chelator and provides cardioprotection against anthracycline toxicity.
Jump to

Quality Control

Batch: Purity: 99.95%
99.95

Solubility

In vitro
Batch:

DMSO : 166.7 mg/mL (621.38 mM) Ultrasonicated;
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 268.27 Formula

C11H16N4O4

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 24584-09-6 -- Storage of Stock Solutions

Synonyms ICRF-187 SMILES CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

In vitro

Topoisomerase 2 (Top2) inhibition with dexrazoxane combined with dBET6 in HeLa cells increases DNA damage signaling at proximal time points.

In vivo

Dexrazoxane prevents doxorubicin induced late-onset cardiomyopathy and also protected the cardiac mitochondria from acquired ultrastructural, genetic and functional damage.

References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-07-27)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07654426 RECRUITING
Diffuse Large B-cell Lymphoma (DLBCL); Cardiotoxicity; Lymphoma
Beth Israel Deaconess Medical Center
2026-08-31 PHASE2
NCT03126916 RECRUITING
Ganglioneuroblastoma; Ganglioneuroblastoma, Nodular; Neuroblastoma
Children's Oncology Group
2018-05-14 PHASE3
NCT04293562 RECRUITING
Acute Myeloid Leukemia
Children's Oncology Group
2020-07-21 PHASE3
NCT06647953 RECRUITING
Pleuropulmonary Blastoma
Children's Oncology Group
2025-03-21 PHASE3
NCT06220032 RECRUITING
DLBCL - Diffuse Large B Cell Lymphoma
Stichting Hemato-Oncologie voor Volwassenen Nederland
2024-08-15 PHASE3
NCT05292664 RECRUITING
Myelodysplastic Syndromes, de Novo; Myelodysplastic Syndromes, Secondary; Myelodysplastic Syndromes, Previously Treated; Treatment-Related Acute Myeloid Leukemia; Therapy-Related Myelodysplastic Syndrome; Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia With Failed Remission; Lymphoblastic Lymphoma, in Relapse; Lymphoblastic Lymphoma, Refractory; Acute Leukemia of Ambiguous Lineage in Relapse; Acute Leukemia of Ambiguous Lineage
Andrew E. Place, MD
2023-03-29 PHASE1

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.